Ironwood Pharmaceuticals (IRWD) vs Mentari Therapeutics (MTRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Mentari Therapeutics is the larger company by market cap ($856.9 million vs $778.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRWD | MTRI |
|---|---|---|
| Share price | $4.70 | $14.70 |
| Market cap | $778.09M | $856.94M |
| 1-day change | -0.21% | -3.57% |
| YTD return | +39.47% | — |
| 1-year return | +48.73% | — |
| 5-year return | -57.89% | — |
| P/E ratio (TTM) | 5.22 | — |
| Forward P/E | 3.00 | — |
| EPS (TTM) | $0.90 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $296.15M | — |
| Revenue growth (YoY) | -15.72% | — |
| Net income (latest FY) | $24.02M | — |
| Operating margin | 33.26% | — |
| Net margin | 8.11% | — |
| 52-week high | $5.78 | $23.30 |
| 52-week low | $2.95 | $5.75 |
| Distance from 52-week high | -18.69% | -36.91% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +31.49% | — |
| Average volume | 2.15M | 19.42K |
| Shares outstanding | 165.55M | 58.30M |
| Employees | 100 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Mentari Therapeutics
MTRI stock →Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.
Health Care · Biotechnology: Pharmaceutical Preparations
IRWD vs MTRI FAQ
Which is bigger, Ironwood Pharmaceuticals or Mentari Therapeutics?
Mentari Therapeutics (MTRI) is larger, with a market capitalization of $856.94M compared with $778.09M for Ironwood Pharmaceuticals (IRWD).
Are Ironwood Pharmaceuticals and Mentari Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.